BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 12778772)

  • 1. [Fabry disease: new clinical research--current therapeutic perspectives].
    Beck M
    Wien Klin Wochenschr; 2003 Apr; 115(7-8):215-7. PubMed ID: 12778772
    [No Abstract]   [Full Text] [Related]  

  • 2. Anderson-Fabry disease in Austria.
    Lorenz M; Hauser AC; Püspök-Schwarz M; Kotanko P; Arias I; Zodl H; Kramar R; Paschke E; Voigtländer T; Sunder-Plassmann G
    Wien Klin Wochenschr; 2003 Apr; 115(7-8):235-40. PubMed ID: 12778775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Agalsidase: a second look. With hindsight: full data challenge efficacy.
    Prescrire Int; 2003 Oct; 12(67):168-71. PubMed ID: 14619828
    [No Abstract]   [Full Text] [Related]  

  • 4. Spotlight on agalsidase beta in Fabry disease.
    Keating GM; Simpson D
    BioDrugs; 2007; 21(4):269-71. PubMed ID: 17628124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Agalsidase beta (Fabrazyme) for Fabry disease.
    Med Lett Drugs Ther; 2003 Sep; 45(1165):74-5. PubMed ID: 12968124
    [No Abstract]   [Full Text] [Related]  

  • 6. Agalsidase Beta: a review of its use in the management of Fabry disease.
    Keating GM; Simpson D
    Drugs; 2007; 67(3):435-55. PubMed ID: 17335299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Fabry disease: Pathogenesis, pathophysiology, and therapy].
    Utsumi K
    Nihon Rinsho; 2006 Feb; 64 Suppl 2():537-40. PubMed ID: 16523950
    [No Abstract]   [Full Text] [Related]  

  • 8. Pediatrics: implementing the promise of early intervention for Fabry disease.
    Raas-Rothschild A
    Clin Ther; 2007; 29 Suppl A():S6. PubMed ID: 17580239
    [No Abstract]   [Full Text] [Related]  

  • 9. Fabry disease: a treatable lysosomal storage disorder.
    Phadke SR; Mandal K; Girisha KM
    Natl Med J India; 2009; 22(1):20-2. PubMed ID: 19761154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Agalsidase alfa--a preparation for enzyme replacement therapy in Anderson-Fabry disease.
    Beck M
    Expert Opin Investig Drugs; 2002 Jun; 11(6):851-8. PubMed ID: 12036428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enzyme replacement therapy in heterozygous females with Fabry disease: results of a phase IIIB study.
    Baehner F; Kampmann C; Whybra C; Miebach E; Wiethoff CM; Beck M
    J Inherit Metab Dis; 2003; 26(7):617-27. PubMed ID: 14707510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enzyme replacement therapy with agalsidase alfa in pregnant women with Fabry disease.
    Kalkum G; Macchiella D; Reinke J; Kölbl H; Beck M
    Eur J Obstet Gynecol Reprod Biol; 2009 May; 144(1):92-3. PubMed ID: 19233535
    [No Abstract]   [Full Text] [Related]  

  • 13. [CME. Fabry disease: rare but not to be missed].
    Steinack C; Gaspert A; Kovacs R; Nowak A
    Praxis (Bern 1994); 2015 Jul; 104(14):719-29. PubMed ID: 26135721
    [No Abstract]   [Full Text] [Related]  

  • 14. Enzyme replacement in Anderson-Fabry disease.
    Bengtsson BA; Johansson JO; Hollak C; Linthorst G; FeldtRasmussen U
    Lancet; 2003 Jan; 361(9354):352. PubMed ID: 12559898
    [No Abstract]   [Full Text] [Related]  

  • 15. Paradoxical Response to Enzyme Replacement Therapy of Fabry Disease Cardiomyopathy.
    Frustaci A; Russo MA; Chimenti C
    Circ Cardiovasc Imaging; 2016 Aug; 9(8):. PubMed ID: 27486136
    [No Abstract]   [Full Text] [Related]  

  • 16. Agalsidase alfa: specific treatment for Fabry disease.
    Mehta A
    Hosp Med; 2002 Jun; 63(6):347-50. PubMed ID: 12096664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of Enzyme Replacement Therapy and Antidrug Antibodies in Patients with Fabry Disease.
    Lenders M; Brand E
    J Am Soc Nephrol; 2018 Sep; 29(9):2265-2278. PubMed ID: 30093456
    [No Abstract]   [Full Text] [Related]  

  • 18. [Anderson-Fabry's disease: diagnostic problems, therapeutic relevance, and clinical experience in the treatment of the disease with enzyme replacement therapy in nephropathic patients].
    Cianciaruso B; Pisani A; Andreucci MV; Parente N; Andria G; Federico S; Sabbatini M; Sessa A
    G Ital Nefrol; 2003; 20(2):113-9. PubMed ID: 12746795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fabry disease in an oligosymptomatic male.
    Altarescu G; Elstein D
    Isr Med Assoc J; 2011 Mar; 13(3):191-2. PubMed ID: 21608346
    [No Abstract]   [Full Text] [Related]  

  • 20. First treatment for Fabry's disease.
    FDA Consum; 2003; 37(4):4. PubMed ID: 12971327
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.